Stapokibart is a high-efficient, humanized antibody targeting the interleukin-4 receptor alpha subunit (IL-4Rα).
By targeting IL-4Rα, Stapokibart can block both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling.
IL-4 and IL-13 are two key cytokines trigger type II inflammation.
It has demonstrated a favorable safety profile and encouraging efficacy and has been approved for the treatment of moderate to severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyposis, and seasonal allergic rhinitis.
Views: 3